Squarepoint Ops LLC Increases Stock Position in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Squarepoint Ops LLC boosted its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 175.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 85,677 shares of the company's stock after acquiring an additional 54,576 shares during the period. Squarepoint Ops LLC owned about 0.52% of Sensus Healthcare worth $593,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in SRTS. Dimensional Fund Advisors LP grew its holdings in shares of Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock worth $2,620,000 after buying an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock worth $1,039,000 after buying an additional 67,269 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Sensus Healthcare by 99.6% during the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock worth $915,000 after buying an additional 65,994 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Sensus Healthcare by 256.6% during the fourth quarter. Millennium Management LLC now owns 85,329 shares of the company's stock worth $590,000 after buying an additional 61,403 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth $381,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Price Performance

Shares of SRTS traded up $0.14 during mid-day trading on Thursday, reaching $5.03. The stock had a trading volume of 139,121 shares, compared to its average volume of 203,056. Sensus Healthcare, Inc. has a 52-week low of $4.01 and a 52-week high of $9.33. The business's fifty day moving average is $4.62 and its 200 day moving average is $5.94. The firm has a market cap of $82.72 million, a price-to-earnings ratio of 12.58 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. The firm had revenue of $8.34 million during the quarter, compared to analysts' expectations of $7.23 million. As a group, sell-side analysts anticipate that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SRTS. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Wall Street Zen lowered shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a report on Friday, April 4th. Finally, Maxim Group dropped their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.67.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.